Dianthus Therapeutics, Inc. (DNTH) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
7 Times Square
New York, NY 10036
United States of America (the)
Phone
929-999-4055
Website
Sector
Healthcare
Industry
Biotechnology
Employees
92
First IPO Date
June 21, 2018
| Name | Title | Pay | Year Born |
| Marino Garcia | President, Chief Executive Officer & Director | 1.16M | 1966 |
| Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | 786,096 | 1989 |
| Simrat Randhawa | Executive Vice President and Head of R&D | 932,680 | 1970 |
| Adam Veness | Senior Vice President, General Counsel & Secretary | 0 | 1986 |
| Edward G. Carr | Senior VP & Chief Accounting Officer | 0 | 1969 |
| Judson Taylor | Senior Vice President & Head of Technical Operations | 0 | N/A |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. | 0 | N/A |
| Rashieda Gluck | Head of Clinical Development Operations | 0 | N/A |
| Kristina Maximenko | Chief People Officer | 0 | N/A |
| Scott Nogi | Head of Business Operations | 0 | N/A |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.